Neurocrine Biosciences EBITDA 2010-2024 | NBIX

Neurocrine Biosciences EBITDA for the quarter ending December 31, 2024 was $0.123B, a 10.75% decline year-over-year.

  • Neurocrine Biosciences 2024 EBITDA was 0.571B, a 125.05% increase from 2023.
  • Neurocrine Biosciences 2023 EBITDA was 0.254B, a 5.37% decline from 2022.
  • Neurocrine Biosciences 2022 EBITDA was 0.268B, a 94.28% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Neurocrine Biosciences EBITDA 2010-2024 | NBIX

  • Neurocrine Biosciences 2024 EBITDA was 0.571B, a 125.05% increase from 2023.
  • Neurocrine Biosciences 2023 EBITDA was 0.254B, a 5.37% decline from 2022.
  • Neurocrine Biosciences 2022 EBITDA was 0.268B, a 94.28% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$80.4B
Zoetis (ZTS)$70.5B
Takeda Pharmaceutical (TAK)$44.1B
Daiichi Sankyo, - (DSNKY)$43.3B
Sandoz Group AG (SDZNY)$20.6B
Merck (MKKGY)$18.5B
Astellas Pharma (ALPMY)$17.5B
Summit Therapeutics (SMMT)$17B
United Therapeutics (UTHR)$16.4B
Shionogi (SGIOY)$12.3B
Orion OYJ (ORINY)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.7B
Corcept Therapeutics (CORT)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Stevanato Group S.p.A (STVN)$6.2B
Ionis Pharmaceuticals (IONS)$5.2B
Grifols, S.A (GRFS)$5.2B
Ono Pharmaceutical (OPHLF)$4.7B
Recursion Pharmaceuticals (RXRX)$4B
Crinetics Pharmaceuticals (CRNX)$3.4B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.2B
Hypermarcas (HYPMY)$2.2B
Soleno Therapeutics (SLNO)$2B
BioCryst Pharmaceuticals (BCRX)$1.9B
NewAmsterdam Pharma (NAMS)$1.8B
Evotec AG (EVO)$1.6B
Dyne Therapeutics (DYN)$1.4B
Ardelyx (ARDX)$1.4B